Get started
AIM ImmunoTech Inc.AIM ImmunoTech Inc.AIM ImmunoTech Inc.

AIM ImmunoTech Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AIM chart


Full chart

AIM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪13.90 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.4726 USD
Net income (FY)
‪−28.96 M‬ USD
Revenue (FY)
‪202.00 K‬ USD
Shares float
‪57.97 M‬
Beta (1Y)
1.11

Employees


Employees (FY)
26
Change (1Y)
+2 +8.33%
Revenue / Employee (1Y)
‪7.77 K‬ USD
Net income / Employee (1Y)
‪−1.11 M‬ USD

About AIM ImmunoTech Inc.


Sector
Health Technology
CEO
Thomas Kenwood Equels
Headquarters
Ocala
Website
aimimmuno.com
Founded
1966
FIGI
BBG000JL6Z80
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AIM news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AIM is 0.2130 USD — it has increased by 4.56% in the past 24 hours. Watch AIM ImmunoTech Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange AIM ImmunoTech Inc. stocks are traded under the ticker AIM.
AIM stock has risen by 9.51% compared to the previous week, the month change is a −4.39% fall, over the last year AIM ImmunoTech Inc. has showed a −57.31% decrease.
We've gathered analysts' opinions on AIM ImmunoTech Inc. future price: according to them, AIM price has a max estimate of 4.50 USD and a min estimate of 1.00 USD. Watch AIM chart and read a more detailed AIM ImmunoTech Inc. stock forecast: see what analysts think of AIM ImmunoTech Inc. and suggest that you do with its stocks.
AIM reached its all-time high on Mar 2, 2000 with the price of 10,036.0128 USD, and its all-time low was 0.1628 USD and was reached on Nov 19, 2024. View more price dynamics on AIM chart.
See other stocks reaching their highest and lowest prices.
AIM stock is 14.09% volatile and has beta coefficient of 1.11. Track AIM ImmunoTech Inc. stock price on the chart and check out the list of the most volatile stocks — is AIM ImmunoTech Inc. there?
Today AIM ImmunoTech Inc. has the market capitalization of ‪13.41 M‬, it has increased by 2.54% over the last week.
Yes, you can track AIM ImmunoTech Inc. financials in yearly and quarterly reports right on TradingView.
AIM ImmunoTech Inc. is going to release the next earnings report on Apr 7, 2025. Keep track of upcoming events with our Earnings Calendar.
AIM earnings for the last quarter are −0.06 USD per share, whereas the estimation was −0.06 USD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about AIM ImmunoTech Inc. earnings.
AIM ImmunoTech Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪17.50 K‬ USD. In the next quarter, revenue is expected to reach ‪100.00 K‬ USD.
AIM net income for the last quarter is ‪−3.70 M‬ USD, while the quarter before that showed ‪−1.84 M‬ USD of net income which accounts for −101.53% change. Track more AIM ImmunoTech Inc. financial stats to get the full picture.
No, AIM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 13, 2024, the company has 26.00 employees. See our rating of the largest employees — is AIM ImmunoTech Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AIM ImmunoTech Inc. EBITDA is ‪−27.67 M‬ USD, and current EBITDA margin is ‪−15.68 K‬%. See more stats in AIM ImmunoTech Inc. financial statements.
Like other stocks, AIM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AIM ImmunoTech Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AIM ImmunoTech Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AIM ImmunoTech Inc. stock shows the sell signal. See more of AIM ImmunoTech Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.